Loading...
Loading...
Available on 1 platform
Sign in to view source links and access this dataset
1,572 reports for nafamostat mesylate and 485 for sodium citrate were mined from the WHO-VigiAccess database up to December 2024. Mengting Xu authored this analysis, which uses disproportionality methods like ROR and PRR to identify safety signals. The study highlights severe immune-related AEs for nafamostat and metabolic complications for sodium citrate.
Primary data file is a 45.3 KB DOCX document, which likely contains a summary or analysis rather than raw structured data tables.